Tessera Therapeutics
Biotechnology ResearchMassachusetts, United States201-500 Employees
Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com
Insights
Gene Writing Technology Tessera Therapeutics' unique Gene Writing™ technology offers a cutting-edge solution that advances genetic medicine beyond current limitations. This innovative approach can be positioned as a superior alternative to traditional genetic therapies, opening doors for partnerships and collaborations with healthcare providers seeking advanced treatment options.
Financial Strength With a significant revenue range of $10M - 50M and a recent $300M funding round, Tessera Therapeutics showcases financial stability and growth potential. Companies offering complementary services or products can capitalize on Tessera's strong financial position to propose mutually beneficial business engagements.
Competitive Landscape Among similar companies in the biotechnology research sector like Fulgent Genetics and Editas Medicine, Tessera Therapeutics stands out with its unique technology and steady financial performance. Leveraging this competitive edge, sales teams can highlight the company's distinctive offerings to attract potential clients and investors looking for innovation and reliability in genetic medicine.
Employee Engagement With a team size ranging between 201-500 employees, Tessera Therapeutics fosters a workforce that is well-equipped to drive innovation and growth. Companies offering HR solutions, training programs, or employee wellness services can target Tessera as a potential client to enhance their workforce engagement strategies and align with a company that values its employees' well-being.
Digital Marketing Tools Tessera Therapeutics utilizes a variety of digital marketing tools such as Craft CMS, SEOmatic, and Google Tag Manager to enhance its online presence and reach a broader audience. Companies specializing in digital marketing services can approach Tessera with proposals to optimize their online strategies, capitalize on their tech stack, and drive lead generation and customer engagement.
Similar companies to Tessera Therapeutics
Fulgent Genetics
387
$50M$100MBeam Therapeutics
507$100M$1BMyriad Genetics
2.6K$100M$1BSarepta Therapeutics
1.5K$100M$1BNatera
3.8K$100M$1BEditas Medicine
334$50M$100MThermo Fisher Scientific
95K$1BCRISPR Therapeutics
436$50M$100MAgilent Technologies
18K$1BGuardant Health
2.9K$100M$1BIllumina
9.1K$1B
Tessera Therapeutics Tech Stack
Tessera Therapeutics uses 8 technology products and services including Craft CMS, BugHerd, Polyfill, and more. Explore Tessera Therapeutics's tech stack below.
- Craft CMSContent Management System
- BugHerdIssue Trackers
- PolyfillJavascript Libraries
- Open GraphMiscellaneous
- PHPProgramming Languages
- SEOmaticSearch Engines
- Tailwind CSSUI Frameworks
- NginxWeb Servers
Media & News
Tessera Therapeutics's Email Address Formats
Tessera Therapeutics uses at least 1 format(s):
| Tessera Therapeutics Email Formats | Percentage |
| FLast@tesseratx.com | 73% |
| First.Last@tesseratx.com | 23% |
| First@tesseratx.com | 3% |
| Last@tesseratx.com | 1% |
Frequently Asked Questions
Where is Tessera Therapeutics's headquarters located?
Tessera Therapeutics's main headquarters is located at Somerville, MA 02143 US. The company has employees across 3 continents, including North AmericaEuropeAsia. What is Tessera Therapeutics's official website and social media links?
Tessera Therapeutics's official website is tesseratx.com and has social profiles on LinkedIn.How much revenue does Tessera Therapeutics generate?
As of November 2024, Tessera Therapeutics's annual revenue reached $35M. What is Tessera Therapeutics's SIC code NAICS code?
Tessera Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).How many employees does Tessera Therapeutics have currently?
As of November 2024, Tessera Therapeutics has approximately 336 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: M. S.Chief Operating Officer: H. P.Chief Scientific Officer: M. H.. Explore Tessera Therapeutics's employee directory with LeadIQ.What industry does Tessera Therapeutics belong to?
Tessera Therapeutics operates in the Biotechnology Research industry. What technology does Tessera Therapeutics use?
Tessera Therapeutics's tech stack includes Craft CMSBugHerdPolyfillOpen GraphPHPSEOmaticTailwind CSSNginx. What is Tessera Therapeutics's email format?
Tessera Therapeutics's email format typically follows the pattern of . Find more Tessera Therapeutics email formats with LeadIQ. How much funding has Tessera Therapeutics raised to date?
As of November 2024, Tessera Therapeutics has raised $300M in funding. The last funding round occurred on Apr 19, 2022 for $300M.
Company Overview
- Headquarters
- Somerville, MA 02143 US
- Website
- tesseratx.com
- SIC Code
- 8733 - Noncommercial Research Organizations
- NAICS Code
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Employees
- 201-500
Funding & Financials
- $300M
Tessera Therapeutics has raised a total of $300M of funding over 3 rounds. Their latest funding round was raised on Apr 19, 2022 in the amount of $300M.
- $10M$50M
Tessera Therapeutics's revenue is in the range of $10M$50M
Funding & Financials
- $300M
Tessera Therapeutics has raised a total of $300M of funding over 3 rounds. Their latest funding round was raised on Apr 19, 2022 in the amount of $300M.
- $10M$50M
Tessera Therapeutics's revenue is in the range of $10M$50M
Company Leadership
M. S.Chief Executive Officer- H. P.Chief Operating Officer
M. H.Chief Scientific Officer
B. L.Chief Human Resources Officer- M. P.Chief Technology Officer, Cell Therapy
Employee Directory
- M. P.Chief Technology Officer, Cell Therapy
- J. R.Co-Founder
- M. S.Chief Executive Officer
- I. M.Chief Data Officer
- R. C.Co-Founder And Advisor
1-888-653-2347 
support@leadiq.com © LeadIQ, Inc. All rights reserved.
